Filing Flows › Repligen (RGEN) › Q2 2026 › vs Q1 2026
Repligen (RGEN) Q2 2026 vs Q1 2026 (quarter over quarter)
Repligen's revenue rose $9.9M (+5%) from $194M in Q1 2026 to $204M in Q2 2026. The biggest changes: Product +$9.9M (+5%); Royalty −$1K (-2%). Operating margin 6.8% against 8.2% (-1.4 pts).
Repligen, Q2 2026: revenue $204M (+12% year over year), operating margin 6.8%, net earnings $5.0M, operating cash flow $32.8M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 6.8% | 8.2% | -1.4 pts |
| Net margin | 2.5% | 4.3% | -1.8 pts |
| Free cash flow margin | 13.4% | 12.1% | +1.3 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product | $204M | $194M | $9.9M | +5% |
| Royalty | $43K | $44K | −$1K | -2% |
| Revenue | $204M | $194M | $9.9M | +5% |
| Operating profit | $14.0M | $15.9M | −$2.0M | -12% |
| Costs & expenses | $190M | $178M | $11.8M | +7% |
| Pre-tax earnings | $14.2M | $1.8M | $12.4M | +699% |
| Cost of revenue | $94.1M | $86.0M | $8.1M | +9% |
| Research & development | $14.4M | $14.5M | −$41K | -0.3% |
| SG&A | $76.6M | $76.5M | $82K | +0.1% |
| Other operating costs | $5.0M | $1.4M | $3.7M | +272% |
| Net earnings | $5.0M | $8.3M | −$3.3M | -40% |
| Income tax | $9.1M | −$6.6M | $15.7M | — |
| Depreciation & amortization | $19.1M | $19.8M | −$700K | -4% |
| Share-based compensation | $8.0M | $8.3M | −$309K | -4% |
| Working capital & other | $683K | −$8.1M | $8.8M | — |
| Operating cash flow | $32.8M | $28.3M | $4.5M | +16% |
| Free cash flow (OCF − capex) | $27.4M | $23.6M | $3.8M | +16% |
| Capital expenditures | $5.3M | $4.7M | $624K | +13% |
Questions
How much did Repligen's revenue grow quarter over quarter in Q2 2026?
Repligen's revenue rose $9.9M (+5%) from $194M in Q1 2026 to $204M in Q2 2026.
What drove Repligen's revenue change in Q2 2026?
Product +$9.9M (+5%); Royalty −$1K (-2%).